Proton Pump Inhibitors Increase Migraine Risk by 70%
People using proton pump inhibitors (PPIs), such as omeprazole and esomeprazole, are 70% more likely to experience migraines or severe headaches than non-users, according to a study published in Neurology Clinical Practice. Among PPI users, 25% reported migraines or severe headaches, compared to 19% of non-users.
This finding highlights PPIs as the acid-reducing drug class most strongly associated with headache risk, making them a potential concern for individuals with preexisting migraines or frequent headaches.
Blockers Are Linked to a 40% Higher Headache Risk
Histamine H2 receptor antagonists (H2 blockers), such as famotidine and cimetidine, were associated with a 40% increased likelihood of migraines or severe headaches compared to non-users. The study found that 25% of H2 blocker users experienced severe headaches, compared to 20% of those not taking these drugs.
While H2 blockers are less strongly associated with headaches than PPIs, the findings suggest they still pose a measurable risk for individuals prone to migraines.
Antacid Supplements Increase Migraine Prevalence by 30%
The study also linked antacid supplements to migraines and severe headaches, albeit at a lower risk level than PPIs or H2 blockers. Among antacid users, 22% reported migraines or severe headaches, compared to 20% of non-users, translating to a 30% higher likelihood of headaches.
Although commonly viewed as a milder option for managing acid-related issues, antacids may still contribute to headache risk, particularly in frequent users.
Magnesium Deficiency and Migraine Risk May Be Connected
Acid-reducing medications, particularly PPIs, can interfere with magnesium absorption, potentially affecting headache prevalence. The study observed an interaction between magnesium intake and H2 blocker use, suggesting that individuals with lower dietary magnesium may be at greater risk of developing migraines. While this finding is preliminary, it points to the potential role of nutritional factors in mitigating headache risk for users of acid-reducing medications.
Elevated Headache Risk Across Acid-Suppressing Drugs
The study examined data from 11,818 adults, comparing headache prevalence among users and non-users of acid-reducing medications. After adjusting for age, sex, caffeine use, and alcohol consumption, all three drug classes—PPIs, H2 blockers, and antacid supplements—were associated with higher odds of migraines or severe headaches:
- PPIs: 70% higher risk
- H2 blockers: 40% higher risk
- Antacids: 30% higher risk
These findings highlight a consistent trend across acid-suppressing medications, with PPIs presenting the most significant concern.
Reference
Margaret Slavin, Cara L. Frankenfeld, Alexander B. Guirguis, Elizabeth K. Seng. “Use of Acid-Suppression Therapy and Odds of Migraine and Severe Headache in the National Health and Nutrition Examination Survey.” Neurology Clinical Practice. 2024; 14 (3). DOI: 10.1212/CPJ.0000000000200302.
